Truist raises target for Xencor stock to USD 29

Published on 10/15/2026 at 12:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue hit USD 51.22 million from USD 4.52 million. Xencor stock costs EUR 20.35 on October 15, 2026 during trading.

Clinical milestones and valuation

Truist Securities raised its target from USD 27.00 to USD 29.00 on September 28, 2026.
Second-quarter 2026 revenue was USD 51.22 million and net loss was USD 21.73 million.
Xencor stock trades at EUR 20.35 at 12:37 p.m. CEST at Lang & Schwarz on October 15, 2026.

XNCR, US98401F1057, Illustration mit AI erstellt.

Xencor, Inc. (US98401F1057) received a higher price target from Truist Securities, which raised its target from USD 27.00 to USD 29.00 on September 28, 2026, according to Investing.com. Xencor stock was trading at EUR 20.35 at Lang & Schwarz on October 15, 2026 at 12:37 p.m. CEST.

Why Truist lifted its target

Truist linked its revised target to the expected clinical update for XmAb819 at the European Society of Medical Oncology Congress. The source said the update was scheduled for October 25, 2026 and assigned a 70 percent probability to favorable scenarios, while estimating peak XmAb819 revenue at USD 800.00 million, according to Investing.com. The target change gives the clinical program a larger role in the near-term valuation discussion.

Three milestones shape the setup

On July 29, 2026, Xencor agreed to a USD 105.00 million settlement with Alexion over an Ultomiris royalty dispute, according to Inside-Filings. On August 5, 2026, second-quarter revenue reached USD 51.22 million, compared with USD 4.52 million in the first quarter, while net loss narrowed to USD 21.73 million from USD 128.92 million, according to Inside-Filings. On September 28, 2026, Truist raised its target from USD 27.00 to USD 29.00 while maintaining its Buy rating, according to Investing.com.

What dates matter for the pipeline

The next two public milestones are October 18, 2026, when the XmAb819 abstract was scheduled for release, and October 23 to October 27, 2026, when the Phase 1 study was scheduled for presentation in Madrid, according to Investing.com. MarketBeat lists November 4, 2026 as the estimated date for third-quarter results, with the announcement expected after the market close, according to MarketBeat.

Price reflects a clinical-stage profile

Xencor was valued at USD 1.7 billion on October 14, 2026, while its 52-week range stood at USD 10.38 to USD 30.61. The stock was last quoted at USD 23.39 on Nasdaq on October 14, 2026 at 4:00 p.m. ET. The further course of trading is shown by the continuously updated real-time quote of Xencor stock.